EVALUATION OF THE EFFICIENCY AND TOLERABILITY OF MONO THERAPY WITH ORAL ETOPOSIDE IN ELDERLY PATIENTS (70+ YEARS OF AGE) WITH ADVANCED NON SMALL CELL LUNG CANCER AND POOR PERFORMANCE STATUS

Zoran Andrić, Vladimir Kovčin, Slobodanka Crevar, Zafir Murtezani, Sanja Kostić

Abstract


Motivation Until recently it was considered that 65 years is cutoff for defining patients as elderly, but newer reports indicate that this age limit shift to 70 years of age. Elderly patients with advanced non small cell lung cancer, associated comorbidities and poor performance status represent a specific population and a challenge for use of chemotherapy. Primary aim was to evaluate the impact of mono therapy with oral etoposide on overall survival in elderly patients (≥ 70 years of age) with advanced non small cell lung cancer and poor performance status (PS) ≥ 2 (clinical stage IIIb and IV ), and as well to evaluate tolerability of this therapy. Secondary aim was to evaluate response rate.
Methods Retrospectively, medical records of 79 female and male patients with advanced non small cell lung cancer and poor performance status treated with oral etoposide (2x25 mg 20 days/10 days pause) in period from 2007 till 2010 were checked for relevant data. Data regarding demographics, performance status, overall survival, response rates and drug toxicity were collected. For statistical analysis we used Pearson chi-square test, T-test, Kaplan-Meier product limited method and Cox regression.
Results Median overall survival (OS) was 31 weeks, in patients with PS 2 overall survival was 34 weeks, and in group with PS 3 was only 24 weeks. Partial response was registered in 20.2% of patients, stable disease in 41.85 % and disease progression in 38% of patients. Treatment was well tolerated, febrile neutropenia and toxic deaths were not registered. Toxic effects didn't have statistically significant influence on OS.
Conclusion Oral etoposide used as mono therapy has been shown as moderate effective and very safe in treating elderly patients with advanced non small cell lung cancer and poor performance status so it represents a good therapy option for treating this specific population.

 


Keywords


Mono Therapy,Oral etoposide,Elderly patients,Lung Cancer

Full Text:

PDF

References


Jemal A, Bray F, Center M. M, Ferlay J, Ward E. and Forman D, Global cancer statistics. CA: A Cancer Journal for Clinicians, Vol. 61, No. 2, pp. 69–90. 2011, doi: 10.3322/caac.20107

Gridelli C, Perrrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer ;33:2313-2314, 1997 http://dx.doi.org/10.1016/S0959-8049(97)10050-8

Kristjansson SR, Wyller TB. Introduction, ESMO handbook of cancer in senior patients, editors Schrijvers D, Aapro M, Zakotnik B, Audisio R, Halteren H, Hurria H, Informa healthcare, New York – London, p. 1-7, 2010

Schrijvers D. Cancer epidemiology. In: Schrijvers D, Aapro M, Zakotnik B, Audisio R, Halteren H, Hurria H, editors. ESMO handbook of cancer in senior patients, New York – London: Informa healthcare, 2010. p. 8-12.

United Nations. World population prospects. The 2008. revision. United Nations, New York , 2009.

Wildiers H. Cytotoxic and targeted anticancer treatment in the senior cancer patient. In: ESMO handbook of cancer in senior patients, editors Schrijvers D, Aapro M, Zakotnik B, Audisio R, Halteren H, Hurria H, Informa healthcare, New York – London, p. 57-65, 2010.

Li J, Chen P, Dai CH, Li XQ, Bao QL. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy, Oncology, 76(5):355-62. Epub 2009 Mar 25

Slevin ML. Low-dose oral etoposide: a new role for and old drug? J Clin Oncol ;8:1607-9,1990 PMid:2170588

Waits TM, Jonson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol;10:292-6;1992 PMid:1310104

Comis RL, Friedland DM., Good BC. The role of oral etoposide in non-small cell lung carcinoma. Drugs;3:21-30;1999 http://dx.doi.org/10.2165/00003495-199958003-00004 PMid:7165009

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.

Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006

Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist; 6 Suppl 1:4–7; 2001 http://dx.doi.org/10.1634/theoncologist.6-suppl_1-4 PMid:11181997

Product Monograph: Lastet® (etoposide). Nippon Kayaku Co, Ltd., Japan. Revised December 2006.

Schrijvers D. Lung cancer in the elderly. ESMO handbook of cancer in senior patients, editors Schrijvers D, Aapro M, Zakotnik B, Audisio R, Halteren H, Hurria H, Informa healthcare, New York – London, .p. 102-103; 2010

Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol; 30(13):1447-55), 2012 May 1

Albain KS, Bitrain JD, Golomb HM, Hoffman PC, Demeester TR, Skosey C, Noble S and Blough RR. Trial vindesine, etoposide and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma. Cancer Treat Rep; 68:413-5; 1984

Uner A, Coskun U, Yegin A, Yamac D, Gunel N. Single agent oral etoposide in recurrent or advanced solid tumors. Turkish Journal of Cancer. Volume 33, No. 4, 2003.

Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati et al. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol;21(6):1290-5. 2010 Jun http://dx.doi.org/10.1093/annonc/mdp525 PMid:19914959

Katoh O, Yamada H, Hiura K, et al. Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. J Clin Phamarcol; 31(12): 1155-60; 1991 http://dx.doi.org/10.1002/j.1552-4604.1991.tb03689.x PMid:1662234

De Jong RS, Mulder NH, Dijksterhuis, et al. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Research; 15: 2319-30; 1995 PMid:8572646

Fiorica F., A. Stefanelli, S. Princivalle, G. Pascale and F. Cartei, Elderly Lung Cancer Patients and Radiochemotherapy: A Review, Journal of Cancer Therapy, Vol. 3 No. 4; pp. 359-363. 2012 doi: 10.4236/jct.2012.324047.




DOI: http://dx.doi.org/10.12955/emhpj.v6i0.379

Refbacks



Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.